A Modern Approach to Diagnostics, Prediction and Course of Renal Cell Cancer

Abdulla ALMURADOV

A Modern Approach to Diagnostics, Prediction and Course of Renal Cell Cancer

Авторы

Abdulla ALMURADOV a:1:{s:5:"ru_RU";s:4:"TDIU";}

Аннотация

ABSTRACT Annually, about 295 thousand newly diagnosed cases of kidney cancer are registered in the world, and 134 thousand deaths from it. When analyzing the dynamics of epidemiological indicators over the past decades, an increase in the incidence of Renal Cell Cancer(RCC) was revealed, while mortality rates are significantly decreasing, especially in developed countries, which is associated with an increase in the use of medical imaging methods and the detection of small tumors (less than 4 cm), asymptomatic. ... At the time of diagnosis, RCC is detected at stage I in 45% of cases, locally advanced RCC in 33% of cases, and in 25% of cases, the tumor process is disseminated. Currently there are nomograms such asUCLA Integrated staging system (UISS), Stage Size Grade and Necrosis (SSIGN), integrated clinical and pathological prognostic scales for setting a prognosis, determining the duration and frequency of follow-up and determining a high-risk group in order to decide whether to conduct systemic therapy, however, they have a number of disadvantages and are in most cases intended for patients with metastatic RCC. Currently, the most common predictive model used for localized RCC is the Mayo Clinic's Integrated Staging System (UISS) and SSIGN. In connection with the above data, the development of new prognostic scales and nomograms with high accuracy and a personalized approach to the treatment of RCC patients based on risk categories are poorly understood problems and require in-depth study.

Библиографические ссылки

Alekseev B.Ya., Kalpinsky A.S., Nyushko K.M., Taraki I.A., Kaprin A.D. Optimization of sequential targeted therapy. Oncourology. 2016;12(3):22-29.

Apanovich N.V., Peters M.V., Korotaeva A.A., Apanovich P.V., Markova A.S., Kamolov B.Sh., Matveev V.B., KaPKRukhin A.V. Molecular genetic diagnosis of clear cell renal cell carcinoma. Oncourology. 2016; 12 (4): 16-20.

Apanovich N.V., Loginov V.I., Apanovich P.V., Sergeev D.A., Kazubskaya T.P., Kamolov B.Sh., Braga E.A., Matveev V.B. , KaPKRukhin A.V. Joint determination of gene expression and methylation for the diagnosis of clear cell renal cell carcinoma. Oncourology. 2018; 14 (4): 16-21.

Atduev V.A., Amoev Z.V., Danilov A.A., Belsky V.A., Ledyaev D.S., Rykhtik P.I., Sheykhov G.I., Puzanov S.A. Surgical treatment of kidney cancer with extended thrombi of the inferior vena cava: complications and long-term results. Oncourology. 2017; 13 (1): 37-44.

Vikhrova N.B., Dolgushin B.I., Panov V.O., Matveev V.B., Shimanovsky N.L., Dvorova E.K. Radiation diagnostic methods in determining the structure of a tumor thrombus in the inferior vena cava in kidney cancer. Oncourology. 2015; 11 (3): 40-45.

Voroshilova E.A., Apanovich N.V., Nosov D.A., Kaprin A.V., Sokolova I.N., Fedyanin M.Yu. Factors predicting the effectiveness of therapy with mTOR inhibitors and VEGFR inhibitors in patients with metastatic renal cell carcinoma. Oncourology. - 2015. - T.11. - No. 4. - P.34-41.

Gorban N.A., Ivanov S.V., Karjakin O.B., Popo A.M., Varlamov S.A., Ganov D.I. Clinical significance of proliferation and apoptosis markers in patients with clear cell renal cell carcinoma. Oncourology. 2014; 10 (1): 10-15.

Zaridze D.G., Mukeria A.F., Shangina O.V., Matveev V.B. Molecular epidemiology of kidney cancer. Oncourology. 2018; 14(3): 107-119.

Zaridze D.G., Mukeria A.F., Shangina O.V. Risk factors for renal cell carcinoma. Siberian Journal ofOncology. 2018; 17 (5): 77-86.

Zyryanov A.V., Oshchepkov V.N., Burkhanova L.A. Clinical experience with the use of sorafenib in patients with advanced kidney cancer. Oncourology. 2017; 13 (2): 124-127.

Evsyukova OI, Matveev VB Kidney cancer: what's new in 2019. Oncourology. 2019.- T.15.-№4. –S.120-125.

Klyuchagina Yu.I., Sokolova Z.A., Baryshnikova M.A. The role of the PD1 receptor and its ligands PDL1 and PDL2 in tumor immunotherapy. Pediatric Oncology 2017; 4 (1): 49–55.

Kushlinsky N.Ye., Gershtein E.S., Goryacheva I.O., Morozov A.A., Alferov A.A., Bezhanova S.D., Kazantseva I.A., Bazaev V.V. , Matveev V.B. Soluble forms of the PD-1 checkpoint receptor and its ligand PD-L1 in the blood serum of patients with renal cell carcinoma: clinical and morphological correlations. Oncourology. 2019; 15 (1): 15-22.

Kushlinsky NE, Fridman MV, Morozov AA, Gershtein ES, Kadagidze ZG, Matveev VB Modern approaches to kidney cancer immunotherapy. Oncourology. 2018; 14 (2): 54-67.

Loginov V.I., Beresneva E.V., Kazubskaya T.P., Braga E.A., KaPKRukhin A.V. Methylation of 10 microRNA

the optimal sequence for using targeted drugs. Oncourology 2014; (3): 12–21.

Popov S.V., Guseinov R.G., Borisenkov MB, Novikov A.I., Skryabin O.N., Orlov I.N., Zaitsev E.V., Topuzov T.M. , Manikhas G.M., Karlov P.A. Comparative assessment of the survival rate of patients with kidney cancer after endovideosurgical radical nephrectomy and kidney resection. Oncourology. 2013; 9 (2): 21-25.

Rakhimov N.M., Boyko E.V., Alloyev A.A. Vascular endothelial growth factor in lymphoangiogenesis in renal cell carcinoma. Bulletin of the Tashkent Medical Academy. Tashkent, 2017, No. 4. - P. 16–20.

Rakhimov NM, Boyko EV, Tillyashaikhova RM, Aloev BB, Ruziev FZ Comparative characteristics of targeted therapy and immunotherapy in the treatment of locally advanced kidney cancer, Doctor akhborotnomasi. –Samarkad, 2018, No. 1. - S. 95–98.

Tillyashaikhov M.N. Organization of the oncological service of Uzbekistan at the present stage and prospects for further development. Clinical and experimental oncology. 2017.-№1.- С.5-7.

Tillyashaikhov M.N., Rakhimov N.M. The role of lymph node dissection in the surgical treatment of renal cell carcinoma. Oncourology, 2009, №3.- P.13-15.

Tillyashaikhov M.N., Rakhimov N.M., Khashimov R.A. Complications of targeted therapy in the treatment of renal cell carcinoma with metastases to the lymph nodes. Bulletin of the Tashkent Medical Academy.Tashkent, 2017, No. 3. - P. 76–78.

Tillyashaikhov M.N., Rakhimov N.M. Immediate results of new surgical access to regional lymph nodes and great vessels in the treatment of renal cell carcinoma. Medical News. Minsk, 2018, No. 8. - P. 81–84 (14.00.00; No. 82).

Tillyashaikhov M.N., Rakhimov N.M., Boyko E.V., Abdukarimov M.G., Aloyev BB, Khasanov Sh.T. Computed tomography in the diagnosis of tumor thrombosis of the renal and inferior vena cava. Problems of Biology and Medicine. Samarkand, 2018, No. 3. - P. 117–120.

Tillyashaikhov M.N., Boyko E.V., Rakhimov N.M., Otaboev A.Kh., Aloev BB, Khasanov Sh., Aloev BB. The risk of venous thromboembolism in patients with renal cell carcinoma with intralaminar invasion of the inferior vena cava after surgery with a fragmented tumor thrombus. Doctor Akhborotnomasi. - Samarkand, 2018, No. 3. - P. 29–35.

Tillyashaikhov MN, Rakhimov NM, Tillyashaikhova RM Evolution of views on the diagnosis and treatment of renal cell carcinoma. Medical Journal of Uzbekistan. - Tashkent, 2018, No. 4. - S. 51–55.

Tillyashaikhov MN, Yusupbekov AA, Yusupov Sh.Kh., Valieva RM, "The use of everolimus in patients with metastatic kidney cancer", Journal of Theoretical and Clinical Medicine. 2016.-No.5 S. 167-169.

Tillyashaikhov M.N., Yusupbekov A.A., Yusupov Sh.Kh., Khodzhitoev S.V., Tillyashaikhova R.M."Comparative analysis of the results of organ-preserving operations and nephrectomy in early kidney cancer" Uzbekistan. 2017.-no. 2 S. 33-38.

Chve S.D., Atakhanova N.E., Kakhkharov A.Zh. Tissue matrix technology in clinical-morphological and molecular-genetic research of breast cancer. Bulletin of the Tashkent Medical Academy. - Tashkent, 2018, No. 2. - P. 46–48.

Yusupbekov AA, Valieva RM "Results of organ-preserving operations in kidney cancer". Journal of the Bulletin of the Association of Physicians of Uzbekistan. 2016.-№ 3. P. 21-25.

Yusupbekov AA, Valieva RM, "Modern view on the surgical treatment of kidney cancer". Bulletin of the Tashkent Medical Academy. 2016.-№3. 6-11.

Yurmazov ZA, Spirina LV, Usynin EA, Kondakova IV, Slonimskaya EM. Molecular parameters associated with the effectiveness of everolimus therapy in patients with disseminated kidney cancer. Siberian Journal of Oncology. 2016; 15 (2): 42-47.

AbelEJ, MastersonTA, KaramJA, MasterVA, MargulisV, HutchinsonR, etal. Predictive nomogram for recurrence following surgery for nonmetastatic renal cell cancer with tumor thrombus. J Urol 2017;198:810–6

Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging(2016) 43:464–73.

Amato R.J.Emerging Research and Treatments in Renal Cell Carcinoma. InTech. -2012. - P.23-56.

Ascierto M.L., McMiller T.L., Berger A.E., Danilova L,, Anders R.A., Netto G.J., Xu H., Pritchard T.S., Fan J., Cheadle C., Cope L., Drake C.G., Pardoll D.M., Taube J.M., Topalian S.L. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research. - 2016. - V.4. - I.9. - P.726-33.

Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92(5): 843–846.

Basu, A.; Yearley, J.H.; Annamalai, L.; Pryzbycin, C.; Rini, B. Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens. Am. J. Clin. Pathol., 2019, 151, 217–225.

Baytekin F.1., Tuna B., Mungan U. et al. Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma. Urol. Oncol., 2011. - V.29. - I.5. - P.502-7.

Beisland CJ, Klepp TB, Axcrona O, Torgersen U, Kowalski KM, Solli J, Sandin O, Oldenburg R. J. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study. Onco Targets Ther., 2017; 10: 371–385.

Beleut M., Zimmermann Ph., Baudis M. et al. Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. BMC Cancer, 2012, №12, P.310.

Bluemke K., Bilkenroth U.et al. Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev., 2009, 18(8).

Bex A. Follow-up for renal cell carcinoma: absence of evidence and beyond.Eur Urol Focus, (2016) 1(3):282–3.

Beuselinck B., Job S. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res. 2015 Mar 15;21(6):1329-39.

Brannon A., Reddy Anupama, Seiler Michael et al. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer, 2010, V.1, I.2, P.152-163.

Cairns P. Bioscience Signaling pathways in renal cell carcinoma. Cancer Biology & Therapy, 2010, V.10, I.7, P.658-664.

Cairns P. Renal Cell Carcinoma. Cancer Biomark. - 2011. - V.9(1-6). - P.461-473.

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499, 43–49.

Caoili E.M., Davenport M.S. Role of Percutaneous Needle Biopsy for Renal Masses. SeminInterventRadiol., 2014. - V.31. - N.1. - P.20-26.

Capitanio U, Leibovich BC. The rationale and the role of lymph node dissection in renal cell carcinoma. WorldJ Urol., (2017) 35(4):497–506.

Casuscelli J., Vano Y-A., Fridman W.H., Hsieh J.J. Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice. Kidney Cancer. - 2017. - V.1. - P.3-13.

Chang Y., An H., Xu L., Zhu Y. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. British Journal of Cancer. -2015. - V.113. - P.626-633.

Chang Hwan Choi, Kyu Ho Kim, Ju Young Song et al. Construction of High-Density Tissue Microarrays at Low Cost by Using Self-Made Manual Microarray Kits and Recipient Paraffin Blocks. TheKoreanJournalofPathology 2012; 46: 562-568.

Chamie K, Donin NM, Klopfer P et al. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncol., 2017; 3(7): 913–920.

Choueiri, T.K.; Larkin, J.; Oya, M.; Thistlethwaite, F.; Martignoni, M.; Nathan, P.; Powles, T.; McDermott, D.;Robbins, P.B.; Chism, D.D.; et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol., 2018, 19, 451–460.

Chechlinska M., Kowalewska M., Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat. Rev. Cancer. - 2010. -V.10(1). - P.2-3.

Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol., 2003; 21: 3133–3140.

Considine B, Hurwitz ME. Current status and future directions of immunotherapy in renal cell carcinoma. Curr Oncol Rep., 2019;21:34.

Conciatori F, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, et al. Role of mTOR signaling in tumor microenvironment: an overview. Int J Mol Sci., 2018;19.

Creighton C.J., Morgan M., Gunaratne P.H. et al. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. - 2013. - V.499. - P.43-9.

D' Alterio C., Portella L., Ottaiano A. et al. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr. Cancer Drug Targets. - 2012. -V.12. - I.6. - P.693-702.

Dall'Oglio M.F., Coelho R.F., Leite K.R., Sousa-Canavez J.M., Oliveira P.S., Srougi M. Gene expression profile of renal cell carcinoma clear cell type. Int. braz. J. urol. -2010. - V.36. - №4. - P.410.

Dengler V.L., Galbraith M., Espinosa J.M. Transcriptional Regulation by Hypoxia Inducible Factors. Crit. Rev. Biochem. Mol. Biol. - 2014. - V.49. - I.1. - P. 1-15.

Donalisio da Silva R., Gustafson D., Nogueira L. et al. Targeted Therapy for Metastatic Renal Carcinoma: an Update. J. Kidney Cancer and VHL. - 2014. - V.1. - N.6. - P. 6373.

Donskov F, et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer. 2015; 113:1571–1580.

Drabkin H.A., Gemmill R.M. Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC). Adv Cancer Res. - 2010. - V.107. - P.39-56.

Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247.

Erlmeier, F.; Weichert, W.; Schrader, A.J.; Autenrieth, M.; Hartmann, A.; Steffens, S.; Ivanyi, P. Prognostic impact of PD-1 and its ligands in renal cell carcinoma. Med. Oncol. 2017, 34, 99.

Escudier B., Bellmunt J., Negrie S. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J. Clin. Oncol. - 2010. - Vol.28. - P.2144-2150.

Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.,(2014) 25(Suppl 3):iii49–56.

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al.Estimating the global cancer incidence and mortality in 2018: GLOBOCANsources and methods. Int J Cancer 2019;144:1941–53.

Finley D.S., Pantuck A.J., Belldegrun A.S. Tumor Biology and Prognostic Factors in Renal Cell

Carcinoma.The Oncologist. - 2011. - V.16. - P.4-13.

Fisher K.E., Yin-Goen Q., Alexis D., et al. Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.Modern Pathology. - 2014. - V.27. - P.222-230.

Fletcher JW, Djulbegovic B, Soares H, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med., (2008) 49:480–508.

Garcia-Donas J., Esteban E., Leandro-García L. J. et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. The Lancet Oncology. - 2011. - V.12. - I.12. - P.1143 - 1150.

Garcia-Donas J., Leandro-García L.J., González Del Alba A., Morente M., Alemany I., Esteban E., Arranz J.A., Climent M.A., Gallardo E., Castellano D.E., Bellmunt J., Mellado B., Puente J., Moreno F., Font A., Hernando S., Robledo M., Rodríguez-Antona C. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Annals of Oncology. - 2013. - V.24. - P.2409-2414.

Gayed B.A., Youssef R.F., Bagrodia A. et al. Translational Science Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU International. - 2014. - V.113. - I.4. - P.668-673.

Gershman B, Thompson RH, Moreira DM, Boorjian SA, Tollefson MK, Lohse CM, et al. Radical nephrectomy with or without lymph node dissection for nonmetastatic renal cell carcinoma: a propensity score-based analysis. Eur Urol., (2017) 71(4):560–7.

Gershman B, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, et al. Renal cell carcinoma with isolated lymph node involvement: longterm natural history and predictors of oncologic outcomes following surgical resection. Eur Urol.,(2017) 72(2):300–6.

Gieniec KA, Butler LM, Worthley DL, Woods SL. Cancer-associated fibroblasts—heroes or villains? Br J Cancer, 2019;121:293–302.

Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res., 2017;23:4416–28.

A Modern Approach to Diagnostics, Prediction and Course of Renal Cell Cancer